Inebilizumab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Generalized Myasthenia Gravis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also in development:Systemic Lupus Erythematosus · Phase 2

Also approved (7)
US
  • adult patients with immunoglobulin G4-Related Disease (IgG4-RD)FDA label
  • UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.FDA label
Product first approved 2020Outside this platform's coverage
EU
  • add-on to standard therapy for adults with generalised myasthenia gravis who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positiveamgen.com
  • adults with active immunoglobulin G4-related disease (IgG4-RD)Outside this platform's coverageamgen.com
  • Monotherapy for adults with AQP4-IgG seropositive neuromyelitis optica spectrum disorders (Uplizna)Outside this platform's coverageEMA
Product first approved 2022
CN
  • AQP4-antibody positive NMOSD in adults (Xinyue, Hansoh)
Product first approved 2022Outside this platform's coveragewww1.hkexnews.hk
JP
  • Prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica)
Product first approved 2021Outside this platform's coverageeyewire.news

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (6)
Other / comorbidity
NCT07598825 · Amgen
2026-12-18 – 2034-02-11 · Autoimmune Hepatitis, AIH
What this study did
NCT07851220 · Amgen
2026-10-01 – 2033-09-26 · Glomerulonephritis, Membranous
What this study did
NCT04540497 · Amgen
2020-12-04 – 2028-10-31 · IgG4 Related Disease
What this study did
NCT07132398 · Tianjin Medical University General Hospital
2025-09-01 – 2028-08-31 · Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)
What this study did
NCT05198557 · Tanabe Pharma Corporation
2022-07-20 – 2026-08 · Systemic Sclerosis
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT02200770 · MedImmune LLC
2015-04-01 – 2020-11-06 · Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
What this study did
Phase 2 (10)
Generalized Myasthenia Gravis
NCT06987539 · Amgen
2026-07-21 – 2030-03-13 · Generalized Myasthenia Gravis
What this study did
Systemic Lupus Erythematosus
Other / comorbidity
NCT07222553 · Amgen
2026-10-21 – 2031-06-10 · Immunoglobulin G4-related Disease
What this study did
NCT07724834 · Charite University, Berlin, Germany
2026-12-01 – 2029-03-01 · Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
What this study did
NCT04372615 · University of Utah
2022-03-30 – 2028-09-30 · Autoimmune Encephalitis, Encephalitis
What this study did
NCT05549258 · Amgen
2023-07-03 – 2027-04-13 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT04174677 · Amgen
2019-12-27 – 2022-04 · Highly Sensitized Patients on Waiting List for Kidney Transplantation
What this study did
NCT03218163 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2017-09-27 – 2018-04-15 · Multiple Myeloma
What this study did
NCT01453205 · MedImmune LLC
2012-02-27 – 2016-07-11 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01466153 · MedImmune LLC
2012-02-07 – 2016-01-08 · Chronic Lymphocytic Leukemia (CLL)
What this study did
Phase 1/2 (2)
Other / comorbidity
NCT00983619 · MedImmune LLC
2010-04-16 – 2019-03-21 · B-cell Malignancies, Cancer
What this study did
NCT02271945 · MedImmune LLC
2014-12-01 – 2016-05-24 · Relapsed/Refractory Aggressive B-cell Lymphomas
What this study did
Phase 1 (4)
Other / comorbidity
NCT01861340 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014-05 – 2016-07 · Myeloma
What this study did
NCT01585766 · MedImmune LLC
2012-04-24 – 2016-06-20 · Multiple Sclerosis, Relapsing Forms
What this study did
NCT01957579 · AstraZeneca
2011-05-25 – 2015-09-15 · Blood Cancer, Advanced B Cell Malignancies
What this study did
NCT00946699 · MedImmune LLC
2010-03 – 2014-03 · Scleroderma
What this study did
Phase 4 (4)
Other / comorbidity
NCT07010302 · Massachusetts General Hospital
2026-09-01 – 2030-05 · NMOSD
What this study did
NCT07862075 · Ruijin Hospital
2025-10-01 – 2028-09-30 · Type 1 AIP
What this study did
NCT06180278 · Amgen
2024-04-02 – 2028-06-26 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT06212245 · Hansoh BioMedical R&D Company
2024-02-25 – 2025-06-25 · Neuromyelitis Optica Spectrum Disorders
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07159893 · First Affiliated Hospital of Wenzhou Medical University
2025-09 – 2026-09 · Neuromyelitis Optica, Autoimmune Diseases, Demyelinating Autoimmune Diseases, CNS
What this study did

Competitive landscape

This mechanism is crowded: 18 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Systemic Lupus Erythematosus: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Inebilizumab: this drugPhase 2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
AnifrolumabApprovedMonoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)Partial signal
NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138
NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%)
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Weak signal
NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889).
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Obecabtagene Autoleucel (Aucatzyl)
Approved(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Tafasitamab
Approved(overall)
Monoclonal antibodyCD19
Reliable signal(overall)
No reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LitifilimabPhase 3Monoclonal antibodyBDCA2 (CLEC4C), BDCA2 / CD303 (blood dendritic cell antigen 2)Reliable signal
NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3)
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)Phase 3Small moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signalNo reviewed efficacy summary in this indication
AfimetoranPhase 2Small moleculeTLR7/8not yet gradedNo reviewed efficacy summary in this indication
BI 3000202Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Cemacabtagene Ansegedleucel
Phase 2(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
EnvudeucitinibPhase 2Small moleculeTYK2Partial signal
NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed
FrexalimabPhase 2Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
FT819Phase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
ICG318Phase 2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ObexelimabPhase 2Monoclonal antibodyCD19 / FcγRIIbPartial signal
NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed
Rapcabtagene Autoleucel
Phase 2(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SanritatugPhase 2Monoclonal antibodyCD38Weak signalNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
VENT-03Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
Zolacabtagene AutoleucelPhase 2Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
Aritinercept
Phase 1/2(overall)
Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-TPhase 1/2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
BudoprutugPhase 1/2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
DS-7011aPhase 1/2Monoclonal antibodyToll-like receptor 7 (TLR7) (inhibitor)Weak signal
NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants.
LisaftoclaxPhase 1/2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
ANX009Phase 1Antibody fragmentC1qnot yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
Azercabtagene Zapreleucel
Phase 1(overall)
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
BCD-256Phase 1Monoclonal antibodyBDCA2 (CLEC4C)not yet gradedNo reviewed efficacy summary in this indication
BCMA-CD19 Compound CAR (cCAR) T CellsPhase 1Cell therapyBCMA / CD19Weak signal
NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months.
BZE2204Phase 1Cell therapyCD19, CD22, and BCMA (tri-antigen)not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 1Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CizutamigPhase 1Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 1Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
F01Phase 1Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
GSK4527363Phase 1——not yet gradedNo reviewed efficacy summary in this indication
GSK5926371Phase 1Biologic (subtype unspecified)CD19 / CD20 (dual-antigen) with CD3 T-cell engagementnot yet gradedNo reviewed efficacy summary in this indication
HC022Phase 1——Weak signalNo reviewed efficacy summary in this indication
IC19 CAR-TPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
LBL-047Phase 1Protein / enzyme therapeuticBDCA2 (CLEC4C) / TACInot yet gradedNo reviewed efficacy summary in this indication
NIM-1324
Phase 1(overall)
Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PIT565Phase 1Multispecific antibodyCD19 x CD2 x CD3not yet gradedNo reviewed efficacy summary in this indication
SAR448501Phase 1Multispecific antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
UTAA09Phase 1Cell therapyCD19Weak signalNo reviewed efficacy summary in this indication
UTAA91Phase 1Cell therapyCD19 (B cells) and PD-1+ pathogenic T cellsnot yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
ZM001Phase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene GeleucelPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-619
—(overall)
UndisclosedCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
GRI-0803
—(overall)
Small moleculeType 2 NKT cells (activator)not yet gradedNo reviewed efficacy summary in this indication
AB-101 (AlloNK)DiscontinuedCell therapyCell therapynot yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
GLPG3970DiscontinuedSmall moleculeSIK2/3not yet gradedNo reviewed efficacy summary in this indication
GLPG5101
Discontinued
Cell therapyCD19
not yet graded(overall)
No reviewed efficacy summary in this indication
SolcitinibDiscontinuedSmall moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication
Vispacabtagene RegedleucelDiscontinuedCell therapyCD19not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Inebilizumab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
Phase 2Neuromyelitis Optica Spectrum DisorderRecruiting
Est. primary completion 2027-04-13 · NCT05549258 · CT.gov ↗
What to watch
August 2027 (1)
Phase 3Neuromyelitis Optica (NMO), Neuromyelitis Optica Spectrum Disorders (NMOSD)Not yet recruiting
Est. primary completion 2027-08-31 · NCT07132398 · CT.gov ↗
What to watch
2028 (4)
June 2028 (1)
Phase 4Neuromyelitis Optica Spectrum DisorderActive not recruiting
Est. primary completion 2028-06-26 · NCT06180278 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-08-06 · NCT06570798 · CT.gov ↗
What to watch
September 2028 (2)
Phase 2Autoimmune Encephalitis, EncephalitisRecruiting
Est. primary completion 2028-09-30 · NCT04372615 · CT.gov ↗
What to watch
Phase 4Type 1 AIPRecruiting
Est. primary completion 2028-09-30 · NCT07862075 · CT.gov ↗
What to watch
2029 (1)
February 2029 (1)
Phase 2Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID) …Not yet recruiting
Est. primary completion 2029-02-01 · NCT07724834 · CT.gov ↗
What to watch
2030 (2)
January 2030 (1)
Phase 4NMOSDRecruiting
Est. primary completion 2030-01 · NCT07010302 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Generalized Myasthenia GravisRecruiting
Est. primary completion 2030-03-13 · NCT06987539 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 2Immunoglobulin G4-related DiseaseRecruiting
Est. primary completion 2031-06-10 · NCT07222553 · CT.gov ↗
What to watch
July 2031 (1)
Phase 3Autoimmune Hepatitis, AIHRecruiting
Est. primary completion 2031-07-30 · NCT07598825 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Glomerulonephritis, MembranousRecruiting
Est. primary completion 2031-09-27 · NCT07851220 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(5)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 February 2026ApprovalEuropean Commission approves UPLIZNA for generalized myasthenia gravis
EU, EC · Source ↗
11 December 2025ApprovalFDA approves UPLIZNA for generalized myasthenia gravis
US, FDA · Amgen · Source ↗
3 April 2025ApprovalFDA approves UPLIZNA for IgG4-RD
US, FDA · Source ↗
15 October 2024Topline resultMINT Phase 3 primary results
Amgen · Source ↗
5 June 2024Topline resultMITIGATE (NCT04540497) Phase 3 met its primary endpoint
Amgen · Source ↗